When you’re sick or require medical attention, you need to be focused. But emotions and physical limitations can impede the ability of a patient or their family to understand and retain important details, such as instructions for surgical prep or aftercare, which can have a significant impact on a patient’s health outcomes. In fact, an estimated 50 percent of patients don’t experience optimal clinical outcomes because they don’t correctly follow their physician’s instructions.
Digital Health in Clinical Trials
In a new survey on how digital health devices and data impact clinical trials, digital health technology vendor Validic reported:
Sixty percent of respondents said they have used digital health technology to conduct clinical trials.
Ninety-seven percent of respondents said they will increase their use of digital technologies in clinical trials in the next five years.
Mobile apps and in-home clinical-grade devices are currently the most commonly used devices in clinical drug trials, but wearable activity trackers and sensors will be the focus of future use.
Seventy percent of respondents said patient-generated health data (PGHD) could have the greatest impact on improving treatments for chronically ill populations.
Although it would be facetious to say that social media has reached a tipping point into ubiquity, it is only relatively recently that it has been used by pharma to collect and analyze patient data. This use of social media may only be in its infancy but as a quick and inexpensive way to gather large-scale, real-world data it is growing rapidly.
Spending on direct-to-consumer pharmaceutical ads rose 9% to $5.6 billion in 2016 [see note below], in part fueled by a 16% boost in spending from Bristol-Myers Squibb, according to data from Nielsen.
Pfizer and Bristol-Myers Squibb again took the two top spots among drugmakers, spending $1.1 billion and $458 million, respectively, on DTC ads. AbbVie, Eli Lilly, and Allergan rounded out the top five DTC spenders. The Nielsen figures include business to business, outdoor, cinema, television, magazine, newspaper, and radio media spend, but not digital.
Newer brands to the top 20 list in 2016 include Novartis' heart-failure drug Entresto ($122 million), Novo Nordisk's diabetes treatment Victoza ($128 million), Celgene's psoriasis drug Otezla ($96 million), and Eli Lilly's diabetes drug Trulicity ($184 million).
The Celgene ad is under scrutiny by regulators. The drugmaker received an untitled letter from the FDA's Office of Prescription Drug Promotion last year over its DTC ad for Otezla, which said the ad's use of loud music and attention-grabbing visuals downplayed the risk information presented therein (here).
When broken down by channel, pharma companies spent less on cinema, newspaper, and radio media last year but sharply increased their investment in outdoor media by 552%. Business to business, television, and magazine media spend also grew, by 31%, 11%, and 6%, respectively.
Le groupe pharmaceutique français Sanofi a annoncé jeudi le lancement d'essais cliniques "numériques" permettant en particulier de suivre les participants à distance, en partenariat avec la société californienne Science 37.
Cette initiative vise à décentraliser et dématérialiser, grâce au numérique, la conduite (des) essais cliniques. La nouvelle méthode s'appuiera sur les technologies mobiles et la télémédecine.
Patient portals are an easy way for patients and physicians to stay in touch in between visits. That's why they are a key tool for building patient loyalty, reducing staff workloads, and increasing revenues and patient engagement.
They could also be an aid for managing population health — but only if patients in need of services actually use their portal accounts.
Across cities and towns, that's beginning to happen. Of 4.8 million urban patients on the athenahealth network who had doctors' visits between January and August 2016, 33 percent were registered on their physicians' portals.
But outside of urban areas, it's a different story: Just 18 percent of rural patients across the network use a portal.
Working with UK firm Cambridge Cognition the company is piloting the app to monitor and assess cognitive function in patients with MDD, which affects around 350 million around the world.
Nicole Mowad-Nassar, vice president of external partnerships at Takeda Pharmaceuticals USA, said: “This collaboration is part of our strategy to embrace new technology to better understand the patient experience and assist healthcare professionals in creating improved patient care pathways.”
The small 30-patient trials of adults who have been prescribed an antidepressant will evaluate the app's feasibility and compliance, and aims to understand how a wearable's measures of mood and cognition compare to traditional neuropsychological testing and patient reported assessments.
Welcome to the February 28, 2017, edition of Pharma Industry News Update (aka PinUp), which is published every Tuesday and Friday as part of the Pharma Marketing News subscription service. PinUp presents selected content of topical interest from a variety of sources. View the Web version of this issue here: http://bit.ly/PINUP022817
Articles in this issue:
- “2016: A Record-setting Year for Generic Drug Approvals by FDA”; http://sco.lt/59bhlx
- “The Top 10 U.S. Drug Patent Losses for 2017”; http://sco.lt/59bhlx
- “Will You Miss Those ED DTC TV Ads When Viagra & Cialis Go Generic?”; http://sco.lt/5bsTdh
- Over 700 Generics Were Approved by FDA in 2015: http://sco.lt/5cKsan
- FDA Approves First Generic Version of Crestor: http://sco.lt/7YcXYH
- Senators to FDA: "Please Explain" Why the Hell You Stymied EpiPen Competition!: http://sco.lt/6RgsUb
- "Lockstep" Price Increases by #Pharma Competitors Keep Rx & Generic Drug Costs High: http://sco.lt/6mWNsn
- Off-patent Drugs at Brand-Name Prices: A Puzzle for Policymakers: http://sco.lt/6zHDk1
About Pharma Industry News Update
The Pharma Industry News Update (aka PinUp) is published every Tuesday and Friday as part of the Pharma Marketing News subscription service. It features curated pharma industry news and views of topical interest from a variety of sources. If you'd like to receive this newsletter, subscribe here.
Thirty years ago, it was a much different world. Patient advocacy groups were far fewer in number and impact, their work relegated largely to promoting awareness, raising money, and helping drug companies promote clinical trials. It wasn’t until a not-so-rare disease — the HIV and AIDS epidemic of the 1980s — that advocates took on a more substantial role. In particular, 1988 stands out as the year that the FDA began working with AIDS activists and awakened to the power of patient engagement.
Pharmaceutical marketers have a wealth of experience producing videos for direct-to-consumer (DTC) advertising (in the U.S.) and disease-awareness piblic service messages worldwide. It's no surprise, therefore, that the Dose of Digital's Pharma and Healthcare Social Media Wiki includes dozens of pharma YouTube channels, or what I like to call "YouPharma".
The Johnson & Johson family of companies, which includes Janssen UK, have been the leaders in launching branded and unbranded YouTube channels. This show features two of the best examples of that. Gary Monk is the person responsible for Janssen-Cilag's "Living with ADHD" YouTube site, which features a video is entitled "ADHD: A day in the life by Janssen-Cilag Ltd." Rob Halper is the person who single-handedly maintains the J&J Health Channel on YouTube, which is a non-branded site with the goal of presenting a better understanding of health and health care issues.
- Describe your YouTube campaign/channel. Who is the intended audience(s)?
- How did you get internal buy in for your digital video campaign?
- How do you define "engagement" with patients via your YouTube channel? Do you allow comments?
- What's your measure(s) of success?
Si l’étiquette apposée est assortie d’un RFID/N.F.C, il devient alors possible de continuer la communication avec la boîte, de regrouper l’information de la boite dans le colis et du colis dans la palette… Il devient surtout possible de connaitre en temps réel le positionnement géographique de la palette et d’assurer un tracking total et sécurisé.